As Chuikyo Begins Pricing Debate of Leqembi, Panelists Urge Safety, Fair Access

Chuikyo General Assembly Meeting on September 27 An all-powerful Japanese reimbursement policy panel on September 27 launched debates on how to set the price of Eisai’s newly approved Alzheimer’s disease (AD) therapy Leqembi (lecanemab). Considering its potentially large market size,...read more